Cancers 2021, 13(16), 4023;, August 10, 2021, by Hanbo Zhang, Stella Koumna, Frédéric Pouliot, Jean-Mathieu Beauregard and Michael Kolinsky.

Contemporary and future landscape of Theranostic applications in prostate cancer with a focus on PSMA ligands. As PSMA Theranostics will soon become the standard of care for the management of prostate cancer, the review underscores the importance of integrating Nuclear medicine physicians into the multidisciplinary team.

Read the article >>